46 patents
Page 2 of 3
Utility
Autoimmune Disorder Treatment Using RXR Agonists
6 May 21
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Autoimmune Disorder Treatment Using RXR Agonists
6 May 21
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 18 Dec 20
Utility
Immunomodulatory and Differentiating Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
22 Apr 21
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
22 Apr 21
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
8 Apr 21
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 16 Dec 20
Utility
Treatment of Muscular Disorders with Combinations of RXR Agonists and Thyroid Hormones
18 Mar 21
The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 7 Oct 20
Utility
Use of an RXR Agonist In Treating HER2+ Cancers
16 Dec 20
The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments.
Martin E. Sanders, Powel H. Brown, M.D., Ph.D.
Filed: 9 Jun 20
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
4 Nov 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 20 Jul 20
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
21 Oct 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 1 Jul 20
Utility
Compounds and Synthetic Methods for the Preparation of Retinoid X Receptor-specific Retinoids
17 Jun 20
Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity.
Roshantha A. Chandraratna, Vidyasagar Pradeep Vuligonda, Thomas Jacks, Peter Wade, Andrew Thompson
Filed: 23 Feb 20
Utility
Treatment of Cancer with Specific RXR Agonists
3 Jun 20
A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
Roshantha A. Chandraratna
Filed: 3 Feb 20
Utility
Treatment of Diseases by Concurrently Eliciting Remyelination Effects and Immunomodulatory Effects Using Selective RXR Agonists
27 May 20
The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
Filed: 6 Jan 20
Utility
Autoimmune Disorder Treatment Using RXR Agonists
20 May 20
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 13 Jan 20
Utility
Autoimmune Disorder Treatment Using RXR Agonists
20 May 20
The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
Filed: 13 Jan 20
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
13 May 20
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 21 Nov 19
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
13 May 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 13 Jan 20
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
13 May 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 13 Jan 20
Utility
Treatment of Nervous System Disorders Using Combinations of RXR Agonists and Thyroid Hormones
13 May 20
Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 13 Jan 20
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
6 May 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 11 Dec 19
Utility
Receptor Subtype and Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
15 Apr 20
Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 11 Dec 19